Aurora Spine Corporation, a global minimally invasive spinal implant company, has announced the first US surgical usage of the company’s AmnioPUR™ liquid allograft products in a lumbar spinal procedure. AmnioPUR was introduced in mid-October at EuroSpine congress in Liverpool and again at the North American Spine Society in New Orleans. AmnioPUR is a multipurpose, chorion-free, cryopreserved allograft, and is derived from the amniotic membrane.
Brent W Johnston, CCO of Aurora Spine, said: “Aurora Biologics, specifically our AmnioPUR product, is another key step in bringing the best products to our worldwide distribution network. The clinical benefit of amnion is well documented, we just made it easier to use.”
AmnioPUR provides an anti-microbial environment with anti-inflammatory characteristics and anti-adheision/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
“The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons the most comprehensive liquid allograft solution in orthopaedics from a provider they trust,” said Trent J Northcutt, Aurora Spine President and CEO.
“Surgeons know Aurora provides modern technologies for today’s patients ailing from spinal complications. Aurora is committed to the development and distribution of advanced biologics and tissue allografts, which make up one of the fastest growing segments of the global market.”
